Samsung Biologics reports Q3 2026 revenue of KRW 1.49 trillion, raises annual growth forecast to 20%

Samsung Biologics reported third-quarter 2026 revenue of KRW 1.49 trillion and operating profit of KRW 640 billion, and raised its annual revenue growth forecast to 20%. The company also announced a KRW 3 trillion rights offering to fund capacity expansion and the planned acquisition of PolyPeptide.

Detected & updated continuously · Source: Nebula